Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance
NonrulemakingOtherFDA-2023-D-5259-0002
Comments
25
Last activity Nov 19, 2025
Deadline
Closed on Mar 22, 2024
Closed Mar 22, 2024
Net supportiSupport minus oppose · campaigns included
+80%
+80% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Dec 22, 2023
- Comment period
- Dec 22, 2023 – Mar 22, 2024
- Agency
- Food and Drug Administration (FDA)
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 25 of 25 comments
100%· analysis complete
Stance breakdown
+80%
Net support
Support21Oppose1Other3
Aggregates include form-letter campaigns. Excluding them, net support is +80% across organic comments.
Who commented
Breakdown by commenter type.
Academic
5
Business
8
Government
1
Individual
6
Trade association
1
Advocacy
4
Comments over time
Weekly arrivals, stacked by stance.
Posted Dec 22, 2023Deadline Mar 22, 2024
Dec 25Jan 29Feb 12Mar 4Nov 17
Support21Oppose1Other3
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Business
100%
0%
0%
Individual
33%
17%
50%
Academic
100%
0%
0%
Advocacy
100%
0%
0%
Government
100%
0%
0%
Trade association
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.